中国临床药学杂志

参考文献

[1] Purohit OP,Anthony C,Radston CR,et al.High-dose intra-venous pamidronate for m etastatic bone pain. Bri J Cancer,1994,70 (3) :5 5 4

[2 ] Compston JE.The therapeutic use of bisphosphonates.Bri MedJ,1994,30 9(7) :711

[3] Rosen CJ,Kessenich CR.Comparative clinical pharmacologyand therapeutic use of bisphosphonates in m etabolic bone dis-ease.Drugs,1996 ,5 1(4) :5 37

[4] Fleisch H. Bisphosphonates:pharmacology and use in the treat-ment of tumour-induced hypercalcaem ia and metastatic bone dis-ease.Drugs,1991,42 :919

[5 ] L ipton A,Glover D,Harvey H,etal. Pamidronate in the treat-mentof bone metastases:Results of2 dose-ranging trials in pa-tients with breast or prostate cancer. Ann Oncol,1994,5(Suppl7) :S37

[6 ] Leyvraz S,Hess U ,Flesch G,et al. Pharmacokinetics ofpamidronate in patients with bone metastases. JNat Cancer In-st,1992 ,84:788

[7]周际昌 .实用肿瘤内科学 .北京 :人民卫生出版社 ,1999:376

[8] Thiebaud D,Leyvraz S,Von Fliedner V,et al.Treatment ofbone m etastases from breast cancer and myeloma withpamidronate.Eur JCancer,1991,2 7:37

[9] Ralston SH,Gallacher SJ. Comparison of three intravenous bis-phosphonates in cancer-associated hypercalcaemia. Lancet,1989,2 :1180